Gentlemen, no need to get at each others' throats! SRX has a...

Gentlemen, no need to get at each others' throats! SRX has a stong lead product which has achieved 2% market penetration in USA. It stands to double the survival of those with colon cancer in the liver and as further data is produced from US trials, which are ongoing, then market penetration will continue to build. SRX is looking at doubling sales in US this coming year and when units sales double for any company in any industry, the sp goes up. SRX has strong management team who have taken very few/no wrong steps. They have a stong team in US and as it builds, so will the company's capacity to deliver scalable growth. My DCF valuation suggests a 12 month sp range of $5-5.5. Main contra factors are that stock is tightly held and many analysts have turned their backs on SRX ever since Cephalon deal did not proceed. CPH have been speaking with SRX and are evaluating making an investment as they have done with BZI, which also has very strong (ex-GE Healthcare) management.